Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of Royalty Pharma (NASDAQ:RPRX) from a hold rating to a buy rating in a report issued on Friday morning.

A number of other equities analysts have also weighed in on the company. UBS Group lowered Royalty Pharma from a buy rating to a neutral rating and set a $28.00 target price on the stock. in a research report on Monday, June 3rd. The Goldman Sachs Group raised their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a buy rating in a research note on Wednesday, August 14th. Finally, Morgan Stanley boosted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an overweight rating in a research report on Thursday, July 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $42.00.

Royalty Pharma Stock Down 0.3 %

Royalty Pharma stock opened at $29.03 on Friday. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $17.23 billion, a PE ratio of 21.66, a PEG ratio of 4.28 and a beta of 0.46. The firm’s fifty day moving average is $27.38 and its 200 day moving average is $28.20. Royalty Pharma has a 12-month low of $25.20 and a 12-month high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The business had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period in the previous year, the company posted $0.85 EPS. As a group, sell-side analysts predict that Royalty Pharma will post 4.04 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Friday, August 16th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.89%. Royalty Pharma’s payout ratio is presently 62.69%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RPRX. Inspire Investing LLC increased its stake in shares of Royalty Pharma by 175.1% during the 1st quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company’s stock worth $1,322,000 after purchasing an additional 27,701 shares during the last quarter. Torray Investment Partners LLC lifted its holdings in Royalty Pharma by 22.6% during the fourth quarter. Torray Investment Partners LLC now owns 505,740 shares of the biopharmaceutical company’s stock valued at $14,206,000 after purchasing an additional 93,107 shares during the last quarter. APG Asset Management US Inc. purchased a new position in shares of Royalty Pharma in the fourth quarter worth about $2,100,000. New Century Financial Group LLC bought a new stake in shares of Royalty Pharma in the first quarter valued at approximately $1,091,000. Finally, Patient Capital Management LLC purchased a new stake in shares of Royalty Pharma during the 4th quarter valued at approximately $35,247,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.